Literature DB >> 17567631

Propensity to release endotoxin after two repeated doses of cefuroxime in an in vitro kinetic model: higher release after the second dose.

G Goscinski1, E Tano, E Löwdin, J Sjölin.   

Abstract

OBJECTIVES: To study endotoxin release from two strains of Escherichia coli after exposure to two repeated doses of cefuroxime in an in vitro kinetic model.
METHODS: Cefuroxime in concentrations simulating human pharmacokinetics was added to the bacterial solution with a repeated dose after 12 h. In another experiment, tobramycin was given concomitantly with the second dose of cefuroxime. Samples for viable counts and endotoxin analyses were drawn before the addition of antibiotics and at 2 and 4 h after each dose.
RESULTS: The propensity to release endotoxin, expressed as log10 endotoxin release (EU)/log10 killed bacteria, was higher after the second than after the first dose, 0.80+/-0.04 and 0.65+/-0.01, respectively, in the ATCC strain and 0.80+/-0.04 and 0.65+/-0.02, respectively, in the clinical strain (P<0.001). Endotoxin was released earlier after the second dose (P<0.001). Addition of tobramycin at the second dose reduced the endotoxin release in comparison with that of cefuroxime alone (P<0.001).
CONCLUSIONS: The propensity to liberate endotoxin is higher after the second dose of cefuroxime than after the first, resulting in a higher release of endotoxin than expected from bacterial count. The release after the second dose can be reduced by the addition of tobramycin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567631     DOI: 10.1093/jac/dkm190

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Characteristics of Escherichia coli Isolated from Bovine Mastitis Exposed to Subminimum Inhibitory Concentrations of Cefalotin or Ceftazidime.

Authors:  Gang Liu; Laidi Ding; Bo Han; Sofie Piepers; S Ali Naqvi; Herman W Barkema; Tariq Ali; Sarne De Vliegher; Siyu Xu; Jian Gao
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

2.  A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6.

Authors:  Anders Thorsted; Salim Bouchene; Eva Tano; Markus Castegren; Miklós Lipcsey; Jan Sjölin; Mats O Karlsson; Lena E Friberg; Elisabet I Nielsen
Journal:  PLoS One       Date:  2019-02-21       Impact factor: 3.240

3.  Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime.

Authors:  Anders Thorsted; Eva Tano; Kia Kaivonen; Jan Sjölin; Lena E Friberg; Elisabet I Nielsen
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model.

Authors:  Paul Skorup; Lisa Maudsdotter; Miklós Lipcsey; Anders Larsson; Jan Sjölin
Journal:  Crit Care       Date:  2020-11-14       Impact factor: 9.097

5.  TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo.

Authors:  Kiyoko Fujita; Iichiro Takata; Ippei Yoshida; Hajime Takashima; Hiroyuki Sugiyama
Journal:  J Antibiot (Tokyo)       Date:  2022-01-05       Impact factor: 2.649

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.